Publications
Search
The Dermatologist
11/20/2024
The US Food and Drug Administration has approved UCB’s BIMZELX (bimekizumab-bkzx) for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS).
APP Institute Oncology
11/20/2024
According to second interim analysis results from the MARIPOSA-2 trial, amivantamab plus chemotherapy improved survival and post-progression outcomes compared to chemotherapy alone among patients with EGFR-mutated advanced non-small cell lung cancer.
First Report Managed Care
11/20/2024
The DIAS3 score, developed and validated using data from over 2200 patients, is a simple clinical tool that predicts the risk of post-CVT epilepsy within 1 and 3 years, showing promise for personalized treatment and decision-making.
Wounds
11/20/2024
In this episode of Wound Care Wednesday, Dr Johnson talks with guest speaker Dr Edward Lee, a clinical plastic surgeon in New Jersey and a Residency Program Director for the Division of Plastic Surgery at the Rutgers New Jersey Medical School. Dr Lee describes how he approaches discussions with patients who struggle with diabetic wounds, including incorporating innovative technology to improve patient compliance.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
11/20/2024
“Our study found that doing these kinds of screenings on patients doesn’t make any marked difference in their long-term survival rates,” said J. Brent Muhlestein, principal investigator of the study and co-director of cardiovascular research at Intermountain Health.
Pharmacy Learning Network
11/20/2024
The Harvard Drug Group, doing business as Major Pharmaceuticals and Rugby Laboratories, is recalling 3 lots of hydralazine hydrochloride tablets. According to the November 20, 2024, US Food and Drug Administration (FDA) Enforcement Report, samples from the lots failed to meet impurity/degradation specifications during routine stability testing.
Pharmacy Learning Network
11/20/2024
Reports of crushed and broken tablets have prompted Cipla USA Inc. to recall a single lot of lanthanum carbonate chewable tablets, according to the November 20, 2024, US Food and Drug Administration (FDA) Enforcement Report.
Pharmacy Learning Network
11/20/2024
Trinity Gold Nutrition is recalling 150 packages of its dietary supplement Trinity Gold for containing undeclared acetaminophen, diclofenac, and phenylbutazone, according to the November 20, 2024, US Food and Drug Administration (FDA) Enforcement Report.
APP Institute Oncology
11/20/2024
According to the preplanned overall survival interim analysis from the phase 3 monarchE trial, abemaciclib plus endocrine therapy continues to show benefit for patients with HR-positive, HER2-negative high-risk early breast cancer.
Gastroenterology
11/20/2024
Dr Hirsh Trivedi details how he approaches the diagnosis and management of metabolic-dysfunction associated fatty liver disease (MAFLD, formerly NAFLD) and metabolic associated steatohepatosis (MASH, formerly NASH.)
Wounds
11/20/2024
In this month's Editorial Message, the Editor-in-Chief, Dr. John C. Lantis, reflects on the purpose behind caring for patients and giving thanks to those who place their trust in wound care providers.
Journal of Invasive Cardiology, CardioVascular
11/20/2024
Video Supplement to "Giant Traumatic External Iliac Artery-Femoral Arteriovenous Fistula" (Clinical Image).
First Report Managed Care, Population Health
11/20/2024
As Robert F. Kennedy Jr’s nomination for Secretary of Health and Human Services (HHS) moves through the Senate, there’s growing discussion about whether a recess appointment could be used to bypass confirmation challenges. The Supreme Court’s 2014 decision in NLRB v Noel Canning plays a key role in this debate (or precedent), as it clarified the limits on a President’s ability to make temporary appointments without Senate approval.
The Mechanics of Recess Appointments
Journal of Invasive Cardiology, CardioVascular
11/20/2024
A 53-year-old woman presented with shortness of breath and fatigue for 1 week. The patient had a medical history of left thigh trauma for more than 20 years.
EMSWorld
11/20/2024
Acquisition expands capabilities in emergency and prehospital care, revolutionizing communication between EMS teams and hospitals for faster clinical workflows and more informed patient care.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
11/20/2024
The study will utilize the Tempus Next platform to identify severe aortic stenosis or moderate to severe mitral regurgitation patients who meet guideline indicated therapy criteria, but do not have a treatment plan in place.
Vascular Disease Management, Journal of Invasive Cardiology, CardioVascular
11/20/2024
Hechingen, November 20th, 2024. With two certificates granted by TÜV, Bentley achieved another break-through in extending indications for its stents in complex aortic interventions. Thanks to one certificate, the Bentley BeGraft stent now is the world’s first on-label bridging device. The second certificate was received for the newly developed BeFlared, the first-to-market dedicated bridging stent for FEVAR (Fenestrated EndoVascular Aneurysm Repair).
Rheumatology & Arthritis
11/20/2024
Earlier identification of patients at risk of developing difficult-to-treat rheumatoid arthritis would allow treatment to begin sooner and optimize outcomes, researchers say.
Rheumatology & Arthritis
11/20/2024
The findings underscore the need for targeted efforts to improve cervical cancer screening in particular among patients with rheumatoid arthritis, given the patients' increased cancer-related mortality.
Rheumatology & Arthritis
11/20/2024
Metabolic syndrome is associated with lower response rates among patients with rheumatoid arthritis on biologic therapy, according to research presented at ACR Convergence 2024.
Featured Webinar
Upcoming Events
November 23 – November 24
December 4 – December 5
December 6 – December 7
December 9 – December 11
December 9 – December 11
December 12 – December 13
December 14 – December 15
February 2 – February 5
February 27 – March 1
March 17 – March 19
